By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Gentronix today said that it has signed a three-year deal with GlaxoSmithKline, under which it will provide the drug maker with its GeneScreen HC and BlueScreen HC genotoxicity assays.

The Manchester, UK-based assay developer said that the agreement extends a pact with GSK for the GreenScreen HC to include the BlueScreen HC in 384-well format, which is its latest human cell reporter-based assay for compound profiling.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.